Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Takeda and Lilly launch insulin sensitizer in first market, expand marketing relationship

Aug. 26, 1999

Meiji Seika also shows interest in study of integrin receptor antagonists

Aug. 26, 1999

Lilly launches reusable growth hormone delivery device for Humatrope

Aug. 26, 1999

MacroChem awarded U.S. patent for Topiglan

Aug. 26, 1999

Amylin acquires patent rights for exendin-4 gene

Aug. 26, 1999

FDA approves new emergency contraceptive product

Aug. 26, 1999

InterMune files BLA for Actimmune for treatment of osteopetrosis

Aug. 25, 1999

Cangene initiates phase III trial of Leucotropin in new indication

Aug. 24, 1999

Lilly presents orally active growth hormone secretagogues at ACS meeting

Aug. 24, 1999

MORE study results: raloxifene reduces risk of spinal fracture

Aug. 23, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...